NGNE vs. ANL, TBPH, FULC, KRRO, PEPG, LXRX, TVTX, TRDA, BMEA, and ANNX
Should you be buying Neurogene stock or one of its competitors? The main competitors of Neurogene include Adlai Nortye (ANL), Theravance Biopharma (TBPH), Fulcrum Therapeutics (FULC), Korro Bio (KRRO), PepGen (PEPG), Lexicon Pharmaceuticals (LXRX), Travere Therapeutics (TVTX), Entrada Therapeutics (TRDA), Biomea Fusion (BMEA), and Annexon (ANNX). These companies are all part of the "pharmaceutical preparations" industry.
Adlai Nortye (NASDAQ:ANL) and Neurogene (NASDAQ:NGNE) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, community ranking, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.
Neurogene's return on equity of 0.00% beat Adlai Nortye's return on equity.
Neurogene received 7 more outperform votes than Adlai Nortye when rated by MarketBeat users.
35.2% of Adlai Nortye shares are owned by institutional investors. Comparatively, 52.4% of Neurogene shares are owned by institutional investors. 1.6% of Neurogene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Adlai Nortye presently has a consensus price target of $30.00, suggesting a potential upside of 130.77%. Neurogene has a consensus price target of $47.25, suggesting a potential upside of 54.21%. Given Neurogene's higher possible upside, equities research analysts clearly believe Adlai Nortye is more favorable than Neurogene.
In the previous week, Neurogene had 18 more articles in the media than Adlai Nortye. MarketBeat recorded 22 mentions for Neurogene and 4 mentions for Adlai Nortye. Neurogene's average media sentiment score of 1.17 beat Adlai Nortye's score of 0.86 indicating that Adlai Nortye is being referred to more favorably in the media.
Summary
Neurogene beats Adlai Nortye on 5 of the 9 factors compared between the two stocks.
Get Neurogene News Delivered to You Automatically
Sign up to receive the latest news and ratings for NGNE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NGNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Neurogene Competitors List
Related Companies and Tools
